Michael W Drazer
Overview
Explore the profile of Michael W Drazer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Homan C, Drazer M, Yu K, Lawrence D, Feng J, Arriola-Martinez L, et al.
Blood Adv
. 2023 Jul;
7(20):6092-6107.
PMID: 37406166
Individuals with germ line variants associated with hereditary hematopoietic malignancies (HHMs) have a highly variable risk for leukemogenesis. Gaps in our understanding of premalignant states in HHMs have hampered efforts...
12.
Hamidi A, Roloff G, Shaw R, Acevedo M, Smith S, Drazer M
Leuk Lymphoma
. 2023 Jun;
64(9):1562-1565.
PMID: 37294121
A growing understanding of the complexities of hematopoietic malignancies necessitates the existence of clinical recommendations that are sufficiently comprehensive. Although hereditary hematopoietic malignancies (HHMs) are increasingly recognized for conferring risk...
13.
Berger Y, Gadiraju M, Dhiman A, Gilliam K, Opalecky B, Chen H, et al.
Cancer
. 2023 Apr;
129(14):2152-2160.
PMID: 37042570
Background: This study aimed to investigate if peritoneal mesothelioma (PM) patients with germline mutations (GM) have distinct surgical characteristics when compared to those without GM. Methods: PM patients were selected...
14.
Roloff G, Wen F, Ramsland A, Artz A, Kosuri S, Stock W, et al.
Haematologica
. 2023 Jan;
108(8):2234-2239.
PMID: 36655425
No abstract available.
15.
Roloff G, Shaw R, OConnor T, Hathaway F, Drazer M
J Genet Couns
. 2023 Jan;
32(3):744-749.
PMID: 36642751
Hereditary hematopoietic malignancies (HHMs) are inherited syndromes that confer the risk of blood cancer development. With the rapid acceleration of next-generation sequencing (NGS) into commercial biotechnology markets, HHMs are increasingly...
16.
Wang P, Segal J, Drazer M, Venkataraman G, Arber D, Gurbuxani S
EJHaem
. 2022 Sep;
3(3):962-965.
PMID: 36051025
No abstract available.
17.
Feurstein S, Trottier A, Estrada-Merly N, Pozsgai M, McNeely K, Drazer M, et al.
Blood
. 2022 Aug;
140(24):2533-2548.
PMID: 35969835
The frequency of pathogenic/likely pathogenic (P/LP) germ line variants in patients with myelodysplastic syndrome (MDS) diagnosed at age 40 years or less is 15% to 20%. However, there are no...
18.
Drazer M, Homan C, Yu K, de Andrade Silva M, McNeely K, Pozsgai M, et al.
Blood Adv
. 2022 May;
6(15):4357-4359.
PMID: 35537115
No abstract available.
19.
Roloff G, Drazer M, Godley L
JCO Precis Oncol
. 2022 Jan;
5:107-122.
PMID: 34994594
As germline predisposition to hematopoietic malignancies has gained increased recognition and attention in the field of oncology, it is important for clinicians to use a systematic framework for the identification,...
20.
White M, Morgan R, Drazer M, Eng O
J Gastrointest Surg
. 2021 Sep;
25(12):3258-3264.
PMID: 34506017
Surgeons encounter neutropenic patients through elective or emergency consultation with increasing regularity. As medical management continues to extend the lives of patients with benign hematologic diseases, hematologic malignancies, solid malignancies,...